InterMune Inc. received approval from for Esbriet, its treatment for the fatal lung-scarring disease idiopathic pulmonary fibrosis
Thursday, March 3, 2011
InterMune IPF drug wins European approval
InterMune Inc. received approval from for Esbriet, its treatment for the fatal lung-scarring disease idiopathic pulmonary fibrosis
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment